Cytosorbents Corp 8-K Summary
Business Context and Reporting Period
Cytosorbents Corporation (Nasdaq: CTSO) filed this Current Report on Form 8-K on November 14, 2022. The filing reports a significant clinical trial milestone for the Company's ongoing research and development activities.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on a specific corporate event.
Material Changes and Events
- Clinical Trial Milestone: The Company announced that 40 of the targeted 120 patients have been enrolled in the Safe and Timely Antithrombotic Removal – Ticagrelor (STAR-T) trial.
- Regulatory Review: This enrollment achievement triggered a pre-specified review by the Data and Safety Monitoring Board (DSMB).
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future performance, or specific risk factors beyond the context of the clinical trial progress. The primary focus is the successful initiation of the DSMB review process.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on the STAR-T trial protocol and DSMB review timeline.
- Confirm the total target enrollment of 120 patients and the remaining enrollment schedule.
- Monitor future filings for the outcome of the DSMB review and any subsequent trial updates.